Tirzepatide is a novel, once-weekly, injectable, dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA, is being developed for the treatment of type 2 diabetes (T2D) and obesity [26] with CV safety demonstrated in the late phase clinical program [27, 28]. This evidence concerns the gene GIP and obesity disorder.